US Edition
Semaglutide Increases Walking Capacity in Patients with Peripheral Artery Disease and Type 2 Diabetes
45 Articles
45 Articles
The medicine Ozempic, whose active substance is semaglutide, has become an effective ally in the fight against obesity, despite the fact that since its emergence on the market both in Spain and internationally it has been accompanied by numerous polemics.Not in vain, this drug was created to treat type 2 diabetes and not to lose weight.Of proven slimming effects, it has now been discovered that Ozempic could have side effects related to the firm…
Benefits of Ozempic in peripheral artery disease consistent across spectrum of diabetes
CHICAGO — Semaglutide 1 mg improves walking distance in patients with early peripheral artery disease and type 2 diabetes, regardless of baseline diabetes duration, HbA1c, BMI and concomitant medication use. Subodh Verma, MD, PhD, FRCSC, professor of medicine, cardiac surgeon and the Canada Research Chair in Cardiovascular Surgery at University of Toronto, presented new insights from
Despite strictly regulated access, prescriptions for anti-obesity drugs such as Ozempic are already costing 76 million euros per year to the Social Security. And the worst would be coming, writes Lecho in his Saturday edition. ...
Until now, the initial prescription of these drugs, such as Wegovy, Mounjaro or Saxenda, had to be performed by a physician specializing in endocrinology-diabetology-nutrition.
So far, the initial prescription of Wegovy, Mounjaro and Saxenda had to be performed by a physician specialized in endocrinology-diabetology-nutrition.
Coverage Details
Bias Distribution
- 84% of the sources are Center
To view factuality data please Upgrade to Premium
